Open letter to Biora Therapeutics shareholders

Read now
Biora Therapeutics Home
Activate the mobile navigation

Reimagining therapeutic delivery

We’re innovating smart-pill technologies designed to deliver the right dose to the right place, safely.

About Biora

NaviCap™ Targeted Oral Delivery Platform

Treatment at the site of disease in the GI tract could improve outcomes for patients with inflammatory bowel disease

Learn More
 
popover=true popoverAnimateThumbnail=true videoFoam=true”> 

BioJet™ Systemic Oral Delivery Platform

Needle-free, oral delivery of large molecules designed to replace injection for better management of chronic diseases.

Learn More
 
popover=true popoverAnimateThumbnail=true videoFoam=true”> 

Press Releases

Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
Biora Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
See More

Publications

Single ascending dose results from a Phase 1 clinical trial of BT-600, a combination product of the NaviCap™ targeted oral delivery platform and tofacitinib
#Targeted Therapeutics
Results of human device function studies for the NaviCap™ Targeted Oral Delivery Platform in healthy volunteers and patients with UC
#Targeted Therapeutics
Evaluation of the pharmacokinetics of GLP-1 receptor agonist delivered through the BioJet™ oral biotherapeutic delivery platform in a porcine model: an update
#Systemic Therapeutics
See More